Recent Posts
- HDT Bio and UTMB Receive MCDC Innovation Prototype Award for Advancing CCHF Vaccine from Lab to Phase 1 Clinical Trial
- FDA Greenlights HDT Bio’s First-in-Class HDT-321 for the Prevention of Deadly Tick-Borne Disease
- Institutional Biosafety Committee
- MalarVx licenses HDT Bio’s repRNA/LION™ Technology for Novel Malaria Vaccine
- Science Direct: Some assembly required: a single-RNA vaccine against enterovirus-D68
Recent Comments
No comments to show.